SRPT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

SR

Mkt Cap

$1.81B

Volume

3.42M

Next Earnings

November 2nd

Chart Financials Earnings News About Insider Filings

Top Research Reports for SpaceX, Dell & KLA Corp.Zacks Research Daily features analysis of 16 major stocks on October 6, 2026. SpaceX benefits from reusable launch technology and Starlink expansion but faces capital requirements. Dell outperforms due to AI infrastructure demand and broad portfolio strength. KLA gains from AI-driven semiconductor demand and process-control intensity. Additional coverage includes analysis of Lockheed Martin's expanded backlog, Deere's pricing actions offsetting commodity headwinds, and concerns about Sarepta's concentrated DMD focus.Zacks Investment Research · Oct 6, 2026

Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta TherapeuticsThe global oligonucleotide therapeutics market is projected to grow from USD 7.7 billion in 2025 to USD 72.1 billion by 2035, expanding at a 23.4% CAGR. Growth is driven by advances in RNA-based medicine, targeted delivery technologies, expanding applications beyond rare diseases into chronic and metabolic conditions, and increasing regulatory approvals. Antisense oligonucleotides lead the market at 39.9% share, while subcutaneous administration dominates at 56.4%. North America commands 57.9% market share.GlobeNewswire Inc. · Sep 15, 2026

2 Beaten-Down Stocks That Still Aren't Worth BuyingThe article argues that Recursion Pharmaceuticals and Sarepta Therapeutics, despite significant stock declines, remain unattractive investments. Recursion has no approved products and faces competition in AI-driven drug discovery. Sarepta struggles with safety concerns around its lead therapy Elevidys and faces an uncertain path to regaining market confidence despite some clinical progress.The Motley Fool · Jul 11, 2026

My Top 3 Biotech Stocks for May 2026With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a speculative small-cap, has regulatory momentum with FDA decisions expected this summer for depression and suicidality treatments.The Motley Fool · May 20, 2026

Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT InvestmentThe global protein synthesis research market is experiencing accelerating growth driven by increased investment in cell and gene therapy research, rising chronic disease prevalence, and expanding healthcare budgets. North America leads with 42.8% market share, while Asia-Pacific infrastructure expansion presents significant growth opportunities. Key market drivers include strong late-stage therapy pipelines and government support through initiatives like the CHIPS and Science Act.GlobeNewswire Inc. · May 18, 2026

Nasdaq 100 Enters Correction As 30-Year Yields Near 5%: What's Moving Markets Friday?U.S. equities tumbled to their lowest levels in nearly seven months on Friday as the Nasdaq 100 officially entered correction territory, down over 10% from January highs. The decline was driven by geopolitical tensions with Iran rejecting ceasefire options, surging crude oil prices, deteriorating consumer sentiment, and rising inflation expectations. The 30-year Treasury yield climbed to 4.958%, threatening to breach 5% for the first time since July 2025, while the Fed rate hike probability by December jumped to nearly 50%.Benzinga · Mar 27, 2026

Stock Market Today: Dow Futures Gain, S&P 500 Slips As Investors Brace For Mega-Cap Earnings— Brand Engagement, Nucor In Focus (UPDATED)U.S. stock futures declined on Monday as investors await mega-cap earnings from tech giants and other major companies. The market is also bracing for the Federal Reserve's interest rate decision on Wednesday, with markets pricing in a 97.2% likelihood of unchanged rates. Key movers include Baker Hughes (up on strong Q4 results), Sarepta Therapeutics (up on trial completion), and Brand Engagement Network (surging 221% on strategic partnership announcement). Analyst Mohamed El-Erian highlights the '2025 Paradox' of resilient markets amid geopolitical tensions.Benzinga · Jan 26, 2026

2 Beaten-Down Stocks That Could Sink Even More in 2026Sarepta Therapeutics and Teladoc Health are identified as two stocks likely to continue declining in 2026. Sarepta faces significant headwinds from safety concerns with its flagship DMD treatment Elevidys, which caused patient deaths and led to restricted access. Teladoc Health struggles with slowing revenue growth, mounting losses, and increased competition in the telemedicine space, particularly affecting its BetterHelp platform.The Motley Fool · Jan 22, 2026

Silver Breaks Above $70, Novo Nordisk Soars 9% On Obesity Pill Approval: What's Moving Markets Tuesday? (CORRECTED)Wall Street traded modestly higher Tuesday with the S&P 500 up 0.4% near 6,900. Strong U.S. GDP data (4.3% annualized growth) prompted traders to scale back Fed rate cut expectations. Novo Nordisk surged 9% following FDA approval of Wegovy in pill form. Precious metals rallied significantly, with silver jumping over 2% to break above $70/ounce (up 140% YTD), gold reaching record highs, and platinum surging 5.5%.Benzinga · Dec 24, 2025

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes ItSarepta Therapeutics experienced a significant stock drop of over 33% after its Phase 3 ESSENCE study for Duchenne muscular dystrophy treatments failed to meet primary endpoints, raising concerns about its drug pipeline and gene therapy safety.Benzinga · Nov 4, 2025

SR

SRPTSarepta Therapeutics,, Inc. Common Stock

SRPT

Pay with—

Available Balance0.00

Your PositionYou don't own any SRPT yet.

Related Tickers

Earnings